NASDAQ:VBLT - Vascular Biogenics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.15 +0.02 (+0.94 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$2.15
Today's Range$2.10 - $2.15
52-Week Range$2.01 - $9.05
Volume35,343 shs
Average Volume62,713 shs
Market Capitalization$63.53 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.69

About Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics logoVascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.

Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VBLT
CUSIPN/A
Phone972-3634-6450

Debt

Debt-to-Equity RatioN/A
Current Ratio6.59
Quick Ratio6.59

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.86 million
Price / Sales4.64
Cash FlowN/A
Price / CashN/A
Book Value$1.68 per share
Price / Book1.28

Profitability

EPS (Most Recent Fiscal Year)($0.37)
Net Income$-10,130,000.00
Net MarginsN/A
Return on Equity-28.67%
Return on Assets-24.29%

Miscellaneous

Employees34
Outstanding Shares29,900,000

Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics (NASDAQ:VBLT) announced its earnings results on Thursday, May, 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.03. The biopharmaceutical company had revenue of $0.16 million for the quarter. View Vascular Biogenics' Earnings History.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Vascular Biogenics.

What price target have analysts set for VBLT?

4 Wall Street analysts have issued twelve-month target prices for Vascular Biogenics' stock. Their predictions range from $3.00 to $4.00. On average, they expect Vascular Biogenics' stock price to reach $3.3333 in the next twelve months. View Analyst Ratings for Vascular Biogenics.

Who are some of Vascular Biogenics' key competitors?

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the folowing people:
  • Prof. Dror Harats, CEO & Director (Age 61)
  • Mr. Amos Ron, CFO, Principal Accounting Officer & Company Sec. (Age 63)
  • Dr. Erez Feige Ph.D., M.B.A., VP of Bus. Operations (Age 44)
  • Dr. Eyal Breitbart Ph.D., VP of Research & Operations (Age 51)
  • Dr. Naamit Sher Ph.D., VP of Drug Devel. & Regulatory (Age 64)

Has Vascular Biogenics been receiving favorable news coverage?

News articles about VBLT stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vascular Biogenics earned a media sentiment score of 0.22 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 48.29 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $2.15.

How big of a company is Vascular Biogenics?

Vascular Biogenics has a market capitalization of $63.53 million and generates $13.86 million in revenue each year. The biopharmaceutical company earns $-10,130,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Vascular Biogenics employs 34 workers across the globe.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 6 JONATHAN NETANYAHU ST., OR YEHUDA L3, 60376. The biopharmaceutical company can be reached via phone at 972-3634-6450 or via email at [email protected]


MarketBeat Community Rating for Vascular Biogenics (VBLT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  342
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vascular Biogenics (NASDAQ:VBLT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Vascular Biogenics in the last 12 months. Their average twelve-month price target is $3.3333, suggesting that the stock has a possible upside of 55.04%. The high price target for VBLT is $4.00 and the low price target for VBLT is $3.00. There are currently 4 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.002.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.3333$3.3333$18.00$16.00
Price Target Upside: 55.04% upside41.84% upside158.99% upside130.22% upside

Vascular Biogenics (NASDAQ:VBLT) Consensus Price Target History

Price Target History for Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics (NASDAQ:VBLT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018HC WainwrightSet Price TargetHold$3.00HighView Rating Details
3/8/2018Chardan CapitalDowngradeBuy ➝ Neutral$25.00 ➝ $3.00LowView Rating Details
3/8/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHighView Rating Details
3/8/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$4.00HighView Rating Details
12/1/2016Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Vascular Biogenics (NASDAQ:VBLT) Earnings History and Estimates Chart

Earnings by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics (NASDAQ:VBLT) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS

Vascular Biogenics (NASDAQ VBLT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018($0.18)N/AView Earnings Details
5/17/2018Q1($0.21)($0.24)$0.16 millionViewListenView Earnings Details
3/15/2018Before Market$0.05$0.24$13.86 millionViewListenView Earnings Details
11/14/2017Q3 2017($0.20)($0.24)ViewN/AView Earnings Details
8/14/20176/30/2017($0.19)($0.18)ViewN/AView Earnings Details
5/15/20173/31/2017($0.17)($0.19)ViewN/AView Earnings Details
3/27/201712/31/2016($0.19)($0.18)ViewListenView Earnings Details
11/10/2016Q316($0.15)($0.12)ViewN/AView Earnings Details
8/15/2016Q2($0.23)($0.14)ViewListenView Earnings Details
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vascular Biogenics (NASDAQ:VBLT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vascular Biogenics (NASDAQ VBLT) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 7.26%
Insider Trading History for Vascular Biogenics (NASDAQ:VBLT)
Institutional Ownership by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics (NASDAQ VBLT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Vascular Biogenics (NASDAQ VBLT) News Headlines

Source:
DateHeadline
VBL Therapeutics to Present at Upcoming Conferences in JuneVBL Therapeutics to Present at Upcoming Conferences in June
finance.yahoo.com - May 24 at 9:14 AM
Vascular Biogenics (VBLT) Given Average Recommendation of "Hold" by BrokeragesVascular Biogenics (VBLT) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 22 at 1:34 AM
Vascular Biogenics (VBLT) Cut to Sell at Zacks Investment ResearchVascular Biogenics (VBLT) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 19 at 3:43 PM
Edited Transcript of VBLT earnings conference call or presentation 17-May-18 12:30pm GMTEdited Transcript of VBLT earnings conference call or presentation 17-May-18 12:30pm GMT
finance.yahoo.com - May 19 at 9:07 AM
Vascular Biogenics (VBLT) Issues  Earnings Results, Misses Estimates By $0.03 EPSVascular Biogenics (VBLT) Issues Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 17 at 12:20 PM
VBL Therapeutics Announces First Quarter 2018 Financial ResultsVBL Therapeutics Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 17 at 9:27 AM
Vascular Biogenics: 1Q Earnings SnapshotVascular Biogenics: 1Q Earnings Snapshot
finance.yahoo.com - May 17 at 9:27 AM
 Analysts Expect Vascular Biogenics (VBLT) to Post -$0.21 Earnings Per Share Analysts Expect Vascular Biogenics (VBLT) to Post -$0.21 Earnings Per Share
www.americanbankingnews.com - May 15 at 11:34 AM
Vascular Biogenics (VBLT) Lowered to Hold at Zacks Investment ResearchVascular Biogenics (VBLT) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:08 PM
VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15
finance.yahoo.com - May 7 at 9:07 AM
Vascular Biogenics (VBLT) to Release Earnings on MondayVascular Biogenics (VBLT) to Release Earnings on Monday
www.americanbankingnews.com - May 7 at 3:46 AM
ValuEngine Upgrades Vascular Biogenics (VBLT) to SellValuEngine Upgrades Vascular Biogenics (VBLT) to Sell
www.americanbankingnews.com - May 2 at 3:12 PM
VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17
globenewswire.com - May 1 at 9:16 AM
Zacks: Brokerages Expect Vascular Biogenics (VBLT) to Post -$0.21 Earnings Per ShareZacks: Brokerages Expect Vascular Biogenics (VBLT) to Post -$0.21 Earnings Per Share
www.americanbankingnews.com - April 27 at 11:24 PM
Vascular Biogenics (VBLT) Enters Oversold TerritoryVascular Biogenics (VBLT) Enters Oversold Territory
finance.yahoo.com - April 27 at 9:46 AM
Vascular Biogenics (VBLT) Given Average Rating of "Hold" by BrokeragesVascular Biogenics (VBLT) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 27 at 1:06 AM
VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACRVBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR
finance.yahoo.com - April 16 at 4:34 PM
Implied Volatility Surging for Vascular Biogenics (VBLT) Stock Options April 12, 2018Implied Volatility Surging for Vascular Biogenics (VBLT) Stock Options April 12, 2018
www.zacks.com - April 13 at 4:38 PM
Vascular Biogenics Ltd (VBLT) Expected to Post Earnings of -$0.21 Per ShareVascular Biogenics Ltd (VBLT) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - April 10 at 11:16 PM
VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16
finance.yahoo.com - April 10 at 9:40 AM
VBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation AuthorityVBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation Authority
finance.yahoo.com - April 9 at 9:29 AM
Vascular Biogenics (VBLT) Receives Buy Rating from HC WainwrightVascular Biogenics (VBLT) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 8 at 11:39 AM
Vascular Biogenics (VBLT) Upgraded to "Hold" by Zacks Investment ResearchVascular Biogenics (VBLT) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 6 at 1:54 PM
Vascular Biogenics Ltd (VBLT) Receives Average Rating of "Hold" from AnalystsVascular Biogenics Ltd (VBLT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 2 at 1:30 AM
HC Wainwright Reiterates "Buy" Rating for Vascular Biogenics (VBLT)HC Wainwright Reiterates "Buy" Rating for Vascular Biogenics (VBLT)
www.americanbankingnews.com - April 1 at 2:38 PM
Vascular Biogenics Ltd (VBLT) Sees Large Drop in Short InterestVascular Biogenics Ltd (VBLT) Sees Large Drop in Short Interest
www.americanbankingnews.com - March 31 at 1:02 AM
 Brokerages Expect Vascular Biogenics Ltd (VBLT) to Post -$0.21 EPS Brokerages Expect Vascular Biogenics Ltd (VBLT) to Post -$0.21 EPS
www.americanbankingnews.com - March 25 at 1:24 AM
HC Wainwright Analysts Give Vascular Biogenics (VBLT) a $3.00 Price TargetHC Wainwright Analysts Give Vascular Biogenics (VBLT) a $3.00 Price Target
www.americanbankingnews.com - March 22 at 1:58 PM
Edited Transcript of VBLT earnings conference call or presentation 15-Mar-18 12:30pm GMTEdited Transcript of VBLT earnings conference call or presentation 15-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 9:12 AM
Vascular Biogenics (VBLT) Raised to "Buy" at Zacks Investment ResearchVascular Biogenics (VBLT) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 17 at 8:12 AM
Vascular Biogenics (VBLT) Posts  Earnings Results, Beats Expectations By $0.19 EPSVascular Biogenics (VBLT) Posts Earnings Results, Beats Expectations By $0.19 EPS
www.americanbankingnews.com - March 15 at 2:25 PM
VBL Therapeutics Announces Year End 2017 Financial ResultsVBL Therapeutics Announces Year End 2017 Financial Results
finance.yahoo.com - March 15 at 9:08 AM
Short Interest in Vascular Biogenics Ltd (VBLT) Expands By 34.6%Short Interest in Vascular Biogenics Ltd (VBLT) Expands By 34.6%
www.americanbankingnews.com - March 13 at 1:54 AM
Vascular Biogenics (VBLT) Set to Announce Earnings on ThursdayVascular Biogenics (VBLT) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 12 at 9:20 AM
ValuEngine Downgrades Vascular Biogenics (VBLT) to Strong SellValuEngine Downgrades Vascular Biogenics (VBLT) to Strong Sell
www.americanbankingnews.com - March 10 at 7:42 PM
Chardan Capital Markets Downgrades Vascular Biogenics Ltd (VBLT) to NeutralChardan Capital Markets Downgrades Vascular Biogenics Ltd (VBLT) to Neutral
www.streetinsider.com - March 9 at 9:46 AM
Chardan Capital Downgrades Vascular Biogenics (VBLT) to NeutralChardan Capital Downgrades Vascular Biogenics (VBLT) to Neutral
www.americanbankingnews.com - March 8 at 8:16 PM
Vascular Biogenics (VBLT) Downgraded by Piper Jaffray Companies to NeutralVascular Biogenics (VBLT) Downgraded by Piper Jaffray Companies to Neutral
www.americanbankingnews.com - March 8 at 8:08 PM
JMP Securities Lowers Vascular Biogenics (VBLT) to Market PerformJMP Securities Lowers Vascular Biogenics (VBLT) to Market Perform
www.americanbankingnews.com - March 8 at 6:52 PM
Vascular Biogenics Ltd (VBLT) Receives Consensus Recommendation of "Hold" from AnalystsVascular Biogenics Ltd (VBLT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 8 at 5:46 PM
Vascular Biogenics (VBLT) Downgraded to "Neutral" at HC WainwrightVascular Biogenics (VBLT) Downgraded to "Neutral" at HC Wainwright
www.americanbankingnews.com - March 8 at 5:29 PM
Vascular Biogenics stock plummets after brain cancer treatment trial failsVascular Biogenics' stock plummets after brain cancer treatment trial fails
finance.yahoo.com - March 8 at 9:36 AM
Vascular Biogenics Target of Unusually Large Options Trading (VBLT)Vascular Biogenics Target of Unusually Large Options Trading (VBLT)
www.americanbankingnews.com - March 7 at 7:26 AM
Vascular Biogenics (VBLT) Downgraded by Zacks Investment ResearchVascular Biogenics (VBLT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 23 at 6:08 PM
 Brokerages Anticipate Vascular Biogenics Ltd (VBLT) to Announce -$0.22 EPS Brokerages Anticipate Vascular Biogenics Ltd (VBLT) to Announce -$0.22 EPS
www.americanbankingnews.com - February 19 at 1:14 AM
VBL Therapeutics Receives Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in JapanVBL Therapeutics Receives Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in Japan
finance.yahoo.com - February 8 at 8:48 AM
Vascular Biogenics (VBLT) Lifted to "Hold" at Zacks Investment ResearchVascular Biogenics (VBLT) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 7 at 2:20 PM
Vascular Biogenics (VBLT) Rating Increased to Hold at ValuEngineVascular Biogenics (VBLT) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - February 4 at 9:02 AM
Vascular Biogenics (VBLT) Upgraded at Zacks Investment ResearchVascular Biogenics (VBLT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 1 at 3:24 PM
Does Vascular Biogenics Ltd’s (NASDAQ:VBLT) CEO Pay Compared Well With Peers?Does Vascular Biogenics Ltd’s (NASDAQ:VBLT) CEO Pay Compared Well With Peers?
finance.yahoo.com - January 25 at 4:18 PM

SEC Filings

Vascular Biogenics (NASDAQ:VBLT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vascular Biogenics (NASDAQ:VBLT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vascular Biogenics (NASDAQ VBLT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.